Our progressive strategy of investing in under-ventured geographies and sectors, coupled with our expertise in building deep relationships with entrepreneurs, executives, and investment partners across the healthcare industry, are significant factors contributing to our success.
Venture the Path Less TraveledTM
A healthcare venture capital firm rooted in the Midwest
Medical Devices
Life Science Tools
& Diagnostics
Tech-Enabled
Care Delivery
Pharma
Adjacencies
Entrepreneurs
We seek innovations that solve (big) healthcare problems and make a transformational impact from teams who are diverse in thought, geography, and demographics.
Investors
We have a proven formula for identifying early-stage startups that can create value in a capital-efficient manner, accelerate portfolio value, and deliver superior returns.
Portfolio Spotlight
We invest in today’s ideas to forge a path for better healthcare tomorrow
Where NeuMoDx started?
Molecular diagnostics is one of the fastest-growing segments within the in-vitro diagnostics market, but existing systems are expensive, complex, and lack sophisticated automation. Through a unique combination of automation and microfluidics, the NeuMoDx Molecular clinical PCR systems offer best-in-class ease of use, throughput, and cost per test.
Where NeuMoDx is today?
Arboretum collaborated with the team to set the strategic direction that helped accelerate the company’s product development timeline and helped recruit new investors. Since Arboretum’s investment, NeuMoDx gained regulatory approvals for its first assays, launched its product, and in September 2020, QIAGEN acquired NeuMoDx to strengthen its portfolio of automated molecular testing.
We fuel the future of healthcare
1B
under management across six funds
76
of the portfolio invested in under-ventured markets over 20 years
40
of all active companies have either a female / minority CEO or founder
16
patient - lives impacted
Shifting the venture capital paradigm
We are proud to be a Midwest venture capital firm operating with transparency, integrity, and approachability to help you realize your entrepreneurial and investor goals. Together, we’ll positively impact patients, communities, and healthcare.
Testimonials
In the News
Clinical study of ECG-based analytic shows average three-hour advance prediction of hemodynamic instability
The Analytic for Hemodynamic Instability (AHI) System™ from Weil Institute spin-off Fifth Eye, Inc. provides clinically significant lead time in predicting onset of instability before vital signs.
Read More
Strata Oncology Announces Appointment of Goz Alhir as Senior Vice President of Commercialization
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter cancer treatment, recently announced the appointment of Goz Alhir as Senior Vice President, Commercialization.
Read More
